Wedbush Equities Analysts Boost Earnings Estimates for FENC

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Research analysts at Wedbush boosted their Q2 2025 earnings estimates for Fennec Pharmaceuticals in a note issued to investors on Tuesday, May 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.05) per share for the quarter, up from their prior estimate of ($0.10). Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q3 2025 earnings at $0.40 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.84 EPS.

A number of other research firms have also recently weighed in on FENC. Craig Hallum raised their price objective on Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, March 11th.

Fennec Pharmaceuticals Trading Up 3.5%

NASDAQ FENC opened at $6.55 on Friday. The firm’s fifty day simple moving average is $5.90 and its two-hundred day simple moving average is $5.91. The firm has a market capitalization of $180.74 million, a P/E ratio of -65.49 and a beta of 0.32. Fennec Pharmaceuticals has a 12-month low of $3.96 and a 12-month high of $7.64.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.08. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. The firm had revenue of $8.51 million during the quarter, compared to analyst estimates of $8.18 million. During the same quarter in the previous year, the business posted $0.41 EPS.

Insider Activity

In related news, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.25, for a total transaction of $52,500.00. Following the sale, the director now directly owns 61,156 shares of the company’s stock, valued at $321,069. This trade represents a 14.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 30,000 shares of company stock valued at $183,500 over the last ninety days. 11.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Solas Capital Management LLC raised its holdings in shares of Fennec Pharmaceuticals by 17.0% during the 4th quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company’s stock worth $14,226,000 after acquiring an additional 327,383 shares during the period. Rosalind Advisors Inc. acquired a new stake in Fennec Pharmaceuticals during the fourth quarter worth about $7,962,000. AIGH Capital Management LLC purchased a new position in Fennec Pharmaceuticals during the first quarter worth about $2,199,000. Geode Capital Management LLC boosted its holdings in Fennec Pharmaceuticals by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 303,090 shares of the company’s stock valued at $1,916,000 after purchasing an additional 3,792 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Fennec Pharmaceuticals by 10.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock valued at $386,000 after buying an additional 5,694 shares during the period. 55.51% of the stock is owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.